Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (479)	8/15/1999 12:18:00 PM
From: Biomaven	Respond to of 717

The 4th quarter loss of $0.46 was above the Zacks consensus of $0.38. No significance in the long run, but enough to cause some short-term weakness. The filing to sell 1.75 million shares is interesting (and unexpected). They don't really need the cash now - with around $50m in cash and a $20m a year run rate, they still had 2 1/2 years cash left. However, when you don't need the cash is the best time to sell shares, and the shares outstanding count is still very moderate. Don't know what they are planning on doing with the extra cash, though. There is actually a reasonable argument that increasing the market cap and the liquidity of this stock will be beneficial to the stock price. Currently, the float is pretty small and the market is often thin, with a big spread - enough to scare off many institutions. Haven't looked at the S-3 in detail yet. Couple of new nuggets I saw, though. On Xcytrin, the NCI trials finally seem to be starting up: In addition to our studies in patients with tumors that have spread to the brain, the National Cancer Institute has agreed to sponsor several clinical trials with XCYTRIN for additional cancer types: TARGETED DISEASE LOCATION STATUS ---------------- -------- ------ Primary Brain Tumor UCLA Medical Center and University of Enrolling patients Southern California Primary Brain Tumor NABTT (New Approaches to Brain Tumor Pending Therapy Consortium, comprised of ten centers) Primary Brain Tumor University of Chicago Pending Pediatric Brain Tumors, Children's Cancer Group (CCG), a Pending including Childhood consortium of U.S. Children's Hospitals Glioma Lung Cancer Ohio State University Pending Pancreatic Cancer University of Pittsburgh Enrolling patients Pancreatic Cancer Johns Hopkins University Oncology Center Pending Pancreatic Cancer University of Chicago Enrolling patients Prostate Cancer Joint Center for Radiation Therapy, Pending Harvard Medical School And on Antrin, we have the following more enthusiastic language: We believe that these results suggest that photoangioplasty of atherosclerosis with ANTRIN has the potential to eliminate or reduce plaque without complications such as thrombosis and reclosure. Additional preclinical studies further indicated that photoangioplasty of atherosclerosis with ANTRIN could be used to treat longer segments of blood vessels, which is not possible with other currently available techniques. ANTRIN's accumulation in plaque and relatively rapid clearance from blood may provide advantages over alternative treatments for atherosclerosis. Removal of inflammatory cells also suggests that ANTRIN may reduce or stabilize vulnerable plaque. Vulnerable plaque is rich in inflammatory cells and prone to rupture causing a sudden blood clot and closure of the vessel. We also believe that photoangioplasty with ANTRIN has potential use in peripheral arterial disease, coronary artery disease and in the treatment of restenosis following balloon angioplasty. <snip> We plan to begin a controlled 375-patient Phase II study with ANTRIN for patients with peripheral arterial disease of the lower extremities later this year. The study will be designed to evaluate both prevention of restenosis following balloon angioplasty and primary treatment of atherosclerosis. Peter

To: scaram(o)uche who wrote (479)	8/16/1999 9:12:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 717

biz.yahoo.com Monday August 16, 8:02 am Eastern Time Company Press Release SOURCE: QLT Phototherapeutics Inc. QLT and CIBA Vision announce regulatory submission seeking approval of Visudyne therapy for wet AMD in the United States ATLANTA and VANCOUVER, Aug. 16 /CNW-PRN/ - CIBA Vision Corporation, the eye care unit of Novartis AG, and QLT PhotoTherapeutics Inc. today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing clearance for Visudyne(TM) therapy for the treatment of wet age-related macular degeneration (AMD), the leading cause of blindness in people over the age of 50 in the western world. (snip)